LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the first quarter ended M…
Final patient dosed in SOLACE phase 3 trial
The last patient has been dosed in the SOLACE phase 3 clinical trial of topical ocular reproxalap in noninfectious anterior uveitis.Time to cure without rescue therapy is the primary outcome measure of the randomized, multicenter, double-masked, parall…
Two-Dimensional Nanodisks Deliver Proteins, Growth Factors to Repair Cartilage
Once cartilage is damaged, there is little that can be done to repair it. Unlike many other tissues, cartilage doesn’t heal well and consequences of injuries and disease can last a lifetime. Now researchers at Texas A&M University have developed an unusual new class of materials that may give cartilage a way of repairing itself. [… (Read more...)
Attain Stability Quad MRI SureScan, World’s Only Active Fixation Left Heart Lead, Approved in U.S.
Cardiac resynchronization therapy (CRT) devices are implanted into heart failure patients to try to improve the efficiency of the heart. How well the therapy ends up working depends very much on the positioning of the electrodes of the leads that stretch into the heart. Quadripolar leads, having two more electrodes than typical, provide a great [&h (Read more...)
XVIVO Perfusion System for Donor Lung Preservation and Assessment Finally Approved by FDA
XVIVO Perfusion, a company based out in Göteborg, Sweden, has been approved to introduce its Xvivo Perfusion System in the United States to effectively renew lungs that would otherwise would not be good enough for transplantation. The system ventilates, oxygenates, and pumps the Steen Solution Perfusate, a buffered extracellular solution, thro (Read more...)
VIDEO: 36-month Yutiq data released
VANCOUVER, British Columbia — EyePoint Pharmaceuticals CEO Nancy Lurker discusses 36-month safety and efficacy data for Yutiq (fluocinolone acetonide intravitreal implant 0.18 mg), released at the Association for Research in Vision and Ophthalmology me…